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Leiomyosarcoma of the Infrarenal Inferior Vena Cava: Management
in Three Cases and a Review of the Literature
M. Davins,1* V. Artigas,2 A. Lo´pez-Pousa,3 S. Vela,2 J. Latorre1 and J.R. Escudero1
Departments of 1Angiology and Vascular Surgery, 2Surgery,
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Leiomyosarcoma (LMS) of the inferior vena cava (IVC) represents 90% of inferior vena cava tumours. It has a poor
prognosis. We present three LMS of infrarenal IVC. Survival was long in two patients in spite of a non-radical resection.
Chemotherapy and repeat surgery was performed for recurrence. The third patient was in complete remission at last
follow-up at 29 months. Mainstay treatment for this tumour is surgical resection. Rescue surgery for local and metastastic
recurrences together with systemic chemotherapy and radiotherapy may improve survival.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd.
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Only 0.5% of leiomyosarcomas (LMS) are of vascular
origin and although rare, such lesions represent 90%
of inferior vena cava (IVC) tumours. Fewer than 250
LMS of the IVC have been reported in the literature.1,2
The clinical features are non-specific, leading to a delay
in diagnosis. Radical surgery is the elective treatment
for local control. However, the recurrences are fre-
quent and the prognosis remains poor. We report three
cases of IVC LMS.
Report
From 1995 to 2005, 56 patients with retroperitoneal
sarcomas were treated at our hospital, a referral centre
for these tumours. Three (5.3%) of these sarcomas
were located in the infrarrenal IVC.
Clinical features and treatments are reported in
Table 1. An infrarenal tumour of IVC was observed
in all patients by echography, CT scan and MR angiog-
raphy. Mean diameter was 9 cm. The preoperative
*Corresponding author. Meritxell Davins, Hospital de la Santa Creu
i Sant Pau, Barcelona, Spain.
E-mail address: mdavins@santpau.es1533–3167  2007 European Society for Vascular Surgery. Publishedhistological study showed a high grade LMS (biopsy
during a hysterectomy in patient 1 (P1) and FNAC
in patient 2 (P2) and patient 3 (P3).
All patients were treated by surgery. P1 received
chemotherapy (CT) prior to surgery. In all patients
we performed marginal excision surgery. (Fig. 1) Par-
tial resection of the IVC was performed in P1 and P2
and excision of the infrarenal IVC without reconstruc-
tion was performed in P3. Resection margins were
positive in two cases and less than 1 cm in the other
case. Postoperatively, all patients received radiother-
apy (RT). Two patients (P1, P2) received postoperative
CT (Doxorubicin and Ifosfamide).
Surgical complications were encountered in one
patient: acute renal failure due to thrombosis of the
right renal artery. This patient also presented oedema
of the lower limbs due to the resection of vena cava;
which resolved with compressive therapy.
Recurrences appeared at 24 months in two patients
(P1, P2). All recurrences were treated with chemother-
apy. P2 presented a solitary hepatic metastasis at 24
months that was treated with CHT followed by rescue
surgery. At 12 months’ follow-up, three hepatic metas-
tasis were also treated with CHT and surgery. Sixty
months after the initial surgery this patient presented
a lung, bone and soft tissue dissemination and shedied.by Elsevier Ltd. Open access under CC BY-NC-ND license.
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spread (Table 1). Although we were unable to perform
radical surgery, P1 survived 32 months and P2 108
months. P3 is presently in complete remission 29
months since diagnosis.
Discussion
According to the literature,3 surgery is the only treat-
ment for LMS that significantly affects survival. Rad-
ical resection with disease-free margin of at least 1 cm
is the recommended surgery but it is not always pos-
sible due to a delayed diagnosis. However, the devel-
opments in diagnostic techniques (CT-scan, MR) and
their increased application enable earlier diagnosis
and improve overall patient survival. RT and CHT
can be used as adjuvant therapies although no sur-
vival increased has been demonstrated.
Hollenbeck et al.3 compared survival in patients in
two groups: patients who underwent radical resection
and those who did not. Higher survival in the radical
surgery group was statistically significant ( p< 0.05).
Hines et al.4 presented 0% survival at 5 years in pa-
tients with positive margins. However, surgery of
hepatic metastases has increased survival and it is
possible to resect the mass and the metastases at the
same time. Furthermore, debulking of intraabdominal
recurrence offers good palliation.5
Although we could not perform radical surgery,
survival was long in our three patients. One patient
survived for 108 months. This patient underwent
repetitive surgery of local recurrence and metastases
Fig. 1. Multilobulated tumour found in P3.
21Leiomyosarcoma of the Infrarenal Inferior Vena Cavaand the result was satisfactory. We consider that the
relatively high survival in our patients was due to
the aggressive surgical treatment of the recurrence.
Another controversial point is the reconstruction of
the IVC. LMS usually grow slowly, so if there is in-
volvement of the IVC with impairment of flow, collat-
erals will develop andwhen present, a resection can be
performed safely. If the IVC is fully patent, it may be
difficult to resect IVE without reconstruction. Before
choosing a surgical technique, it is important to evalu-
ate the previous patency of IVC, determine the seg-
ment to be resected, and assess the patient’s general
status.6 We only encountered oedema in one patient
and this was resolved with compressive therapy.
Hollenbeck et al.1,3 compared the various grades of oe-
demas using several techniques and concluded that
simple ligature, primary reconstruction and autograft
patch caused less oedema than prosthetic grafts. We
consider that simple ligature or primary reconstruc-
tion is the first option with few complications and lim-
ited oedema due to marked collateral circulation.
In conclusion, with the increasing availability of
non-invasive diagnostic techniques, LMS will be diag-
nosed earlier and more precisely, leading to a higher
rate of radical surgery. Together with more aggressive
treatment of recurrences and metastases, overall pa-
tient survival could improve. We consider thatamultidisciplinary team composed of a medical oncol-
ogist, a radiotherapy oncologist, a general surgeon and
a vascular surgeon can provide optimal treatment for
this pathology.
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